Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43273 | 0.89 | — | — | |
| SCHEMBL9111058 | 0.84 | ENPEP (0.38) | ALDH1A1 | |
| SCHEMBL11810443 | 0.84 | ENPEP (0.38) | ALDH1A1 | |
| SCHEMBL181418 | 0.84 | — | — | |
| SCHEMBL12321641 | 0.83 | — | — | |
| SCHEMBL20758116 | 0.83 | — | — | |
| SCHEMBL20833191 | 0.83 | — | — | |
| SCHEMBL1752089 | 0.83 | — | — | |
| SCHEMBL12321180 | 0.83 | — | — | |
| SCHEMBL1482755 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116367909-A | Metal-organic frameworks for carbon dioxide capture | 埃克森美孚技术与工程公司 | 2023-06-30 | — | — | CN | claimed |
| EP-4132586-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | Tiba Biotech LLC (US) | 2023-02-15 | — | — | EP | claimed |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4132586-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | Tiba Biotech LLC (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023015204-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR CANCER DETECTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20200090917-A1 | TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2020-03-19 | — | — | US | disclosed |
| US-10347476-B2 | Tuned synthetic dendrimer calibrants for mass spectrometry | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2019-07-09 | — | — | US | disclosed |
| US-10208240-B2 | Fluid efficiency and flow back enhancer | HALLIBURTON ENERGY SERVICES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9944534-B2 | Reducing aluminosilicate scale in the Bayer process | ECOLAB USA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20110269814-A1 | 2'-F MODIFIED RNA INTERFERENCE AGENTS | Alnylam Pharamaceuticals, Inc. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2009142822-A9 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009142822-A2 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2068886-A2 | LIPID CONTAINING FORMULATIONS | Alnylam Pharmaceuticals Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
| WO-2008042973-A2 | LIPID CONTAINING FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269814-A1 | 2'-F MODIFIED RNA INTERFERENCE AGENTS | AGO2, NSUN2, XRN2 | ALDH1A1 2653/4885 |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885 |
| US-10347476-B2 | Tuned synthetic dendrimer calibrants for mass spectrometry | SRMS, SRM, DNMT1 | ALDH1A1 3320/4885 |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885 |
| US-20200090917-A1 | TUNED SYNTHETIC DENDRIMER CALIBRANTS FOR MASS SPECTROMETRY | SRMS, SRM, DNMT1 | ALDH1A1 3381/4885 |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885 |
| US-20120046478-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | ALDH1A1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.